

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated peptide complex comprising:
a first peptide selected from the group consisting of:
(a1) mammalian phospholipase D (PLD),
(a2) a PLD variant,
(a3) a PLD fragment, and
(a4) a fusion peptide containing (a1), (a2), or (a3); as a first peptide
and
a second peptide selected from the group consisting of
(b1) mammalian actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Akt1, glucose transporter 4 (GLUT4), mammalian target of rapamycin (mTOR), heat shock protein 70 (hsp70), dynamin, munc 18, tubulin, n-nitric oxide synthase (nNOS), integrin beta 3, guanine nucleotide exchange factor H1 (GEF-H1), V-ATPase, phosphoinositide 3-phosphate (PIP3), or dopamine transporter (DAT); as a second peptide
(b2) a variant of (b1),
(b3) a fragment of (b1), and
(b4) a fusion peptide containing (b1), (b2), or (b3).

2. (Currently Amended) The isolated peptide complex of claim 1, wherein the first peptide is PLD-PLD1 or PLD2 and the second peptide is α -actin or β -actin selected from the group consisting of actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Akt1, glucose transporter 4 (GLUT4), mammalian target of rapamycin (mTOR), heat shock protein 70 (hsp70), dynamin, munc 18, tubulin, n-nitric oxide synthase (nNOS), integrin beta 3, guanine nucleotide exchange factor —H1 (GEF-H1), V-ATPase, phosphoinositide 3-phosphate (PIP3), dopamine transporter (DAT).

3. (Currently Amended) The isolated peptide complex of claim 1, wherein the first peptide ~~is the fusion peptide containing PLD, a PLD variant or a PLD fragment~~ contains a detectable tag.

4. (Currently Amended) The isolated peptide complex of claim 1, wherein the second peptide contains a detectable tag ~~is the fusion peptide containing one or more peptide selected from the group consisting of~~ actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Akt1, glucose transporter 4 (GLUT4), mammalian target of rapamycin (mTOR), heat shock protein 70 (hsp70), dynamin, munc-18, tubulin, n-nitric oxide synthase (nNOS), integrin beta-3, guanine nucleotide exchange factor—H1 (GEF-H1), V-ATPase, phosphoinositide-3-phosphate (PIP3), dopamine transporter (DAT), a variant thereof, and a fragment thereof.

5. (Original) The isolated peptide complex of claim 1, wherein the first peptide is linked to the second peptide by a covalent bond.

6. (Withdrawn) A screening method for modulators of the peptide complex according to claim 1, which comprises:

- providing the isolated peptide complex;
- contacting the isolated peptide complex with a test compound; and
- detecting an interaction between the test compound and the isolated peptide complex and/or an interaction change between the first peptide and the second peptide.

7. (Withdrawn, Currently Amended) A screening method for modulators of an interaction between a first peptide ~~selected from the group consisting of~~

- (a1) phospholipase D (PLD),
- (a2) a PLD variant,
- (a3) a PLD fragment, and
- (a4) a fusion peptide containing (a1), (a2), or (a3); and

a second peptide ~~selected from the group consisting of~~

- (b1) actin, aldolase, collapsin response mediator molecule 2 (CRMP-2), phospholipase C- γ 1 (PLC- γ 1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Akt1, glucose transporter 4 (GLUT4), mammalian target of rapamycin (mTOR), heat shock protein 70 (hsp70), dynamin, munc 18, tubulin, n-nitric oxide synthase (nNOS), integrin beta 3, guanine nucleotide exchange factor H1 (GEF-H1), V-ATPase, phosphoinositide 3-phosphate (PIP3), or dopamine transporter (DAT),
- (b2) a variant of (b1),
- (b3) a fragment of (b1), and
- (b4) a fusion peptide containing (b1), (b2), or (b3),

which comprises:

- contacting the first peptide with the second peptide in presence of a test compound; and
- detecting an interaction between the first peptide and the second peptide.

8. (Withdrawn, Currently Amended) The screening method of claim 6, wherein at least one of the first and second peptides ~~is a fusion peptide having~~ contains a detectable tag.

9. (Withdrawn) The screening method claim 6, wherein the contacting step is conducted in a substantially cell free environment.

10. (Withdrawn) The screening method claim 6, wherein the interaction or interaction change between the first peptide and the second peptide is determined in a host cell.

11. (Withdrawn) The screening method claim 6, wherein the detecting comprises measuring the amount of the peptide complex formed with the first and second peptides.

12. (Withdrawn) The screening method claim 6 further comprising generating a data set defining one or more selected test compounds.

13. (Withdrawn) The screening method claim 12, wherein the data set is in a transmittable form.